Mannatech Inc

Mannatech Inc(MTEX)股票分析

$6.740

+0.437 (+6.48%)收盤時

Loading chart…
High
7.190
Open
6.960
VWAP
6.79
Vol
27.55K
Mkt Cap
13.10M
Low
6.430
Amount
186.97K
EV/EBITDA, TTM
0.00

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies.

AI analysis of Mannatech Inc (MTEX)

buy

Mannatech Inc (MTEX) appears to be a good buy right now, primarily due to its recent upward momentum and improving financial metrics. The stock has seen a 5-day change of +6.65% and a significant increase of +40.71% over the past 20 days, indicating strong short-term performance. Additionally, the current RSI is at 61.75, suggesting that the stock is gaining momentum without being overbought. However, investors should be cautious of the net income trend, which has shown significant losses, with a recent EPS of -5.94 in Q4 2025 being a major risk factor.

估值指標

The current forward P/E ratio for Mannatech Inc (MTEX) is 9.57, compared to its 5-year average forward P/E of 1.28.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.28
Current P/E
9.57
高估
4.39
低估
-1.84

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for MTEX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MTEX

$9.48

情境價格

B

Base

Base · 50%MTEX

$7.93

情境價格

B

Bear

Bear · 25%MTEX

$7.87

情境價格

事件時間軸

2026-08-14 (ET)

14:30:00

Mannatech Trading Halted Due to Volatility

14:30:00

Mannatech Trading Resumes

2026-04-07 (ET)

16:00:00

Mannatech Trading Halted Due to Volatility

2024-11-26 (ET)

15:30:47

Mannatech names Robert Toth vice chairman of the board

資訊

MTEX FAQ — answered by Alphio AI

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Mannatech Inc (MTEX) appears to be a good buy right now, primarily due to its recent upward momentum and improving financial metrics. The stock has seen a 5-day change of +6.65% and a significant increase of +40.71% over the past 20 days, indicating strong short-term performance. Additionally, the current RSI is at 61.75, suggesting that the stock is gaining momentum without being overbought. However, investors should be cautious of the net income trend, which has shown significant losses, with a recent EPS of -5.94 in Q4 2025 being a major risk factor.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始